Research institute

Desiccated Coconut Powder Market - Global Growth, Covid-19, Trends and Forecasts 2021 - 2026 - ResearchAndMarkets.com

Monday, September 20, 2021 - 1:58pm

The "Desiccated Coconut Powder Market - Growth, Covid-19, Trends and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Desiccated Coconut Powder Market - Growth, Covid-19, Trends and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Desiccated Coconut Powder Market is projected to grow at a CAGR of 7.45% during the forecast period 2021-2026.
  • Sales of coconut-based ingredients, such as coconut powder, are growing, and these products are widely used as ingredients in various processed food products.
  • Some of the major players in the global desiccated coconut powder market are Primex Coco Products, V V Industries, VIET DELTA, Silvermill Group, Davidsun Coconut Products, and Vittal Agro among others.

Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index

Monday, September 20, 2021 - 12:33pm

Salarius inclusion in the FTSE index will be effective after the U.S. market opens today, Monday, September 20, 2021.

Key Points: 
  • Salarius inclusion in the FTSE index will be effective after the U.S. market opens today, Monday, September 20, 2021.
  • The addition of Salarius to the FTSE Global Micro Cap Index is the latest event in what has been an exceptional year for the company, highlighted by the strengthening of the companys financial position and significant progress in our clinical programs, stated David Arthur, Chief Executive Officer of Salarius Pharmaceuticals.
  • The FTSE Global Micro Cap Index is part of the FTSE Global Equity Index Series (GEIS), which includes 16,000 large-, mid-, small-, and micro-cap securities across 49 developed and emerging markets globally.
  • As of July 30, 2021, The FTSE Global Micro Cap Index had a net market capitalization of $1.89 trillion and included 8,832 constituent companies.

Gerdau Graphene Presents Its Chief Technology Officer (Europe And Asia), Based On Its R&D Center At The University of Manchester

Thursday, September 16, 2021 - 2:00pm

The renowned Scientist, Nurul Alam, PhD in Nanotechnology and Materials Science, now commands the company's Research Center as Gerdau Graphene's European CTO.

Key Points: 
  • The renowned Scientist, Nurul Alam, PhD in Nanotechnology and Materials Science, now commands the company's Research Center as Gerdau Graphene's European CTO.
  • Researching graphene for four years, Gerdau, the largest Brazilian steel producer, has been operating since 2019 within the University of Manchester.
  • In 2021, it launched Gerdau Graphene, a company focused on the application, development, and marketing of graphene enhanced products, with its innumerous potential end products.
  • Gerdau Graphene is a company launched by Gerdau through Gerdau Next, its new business arm.

Gerdau Graphene Presents Its Chief Technology Officer (Europe And Asia), Based On Its R&D Center At The University of Manchester

Thursday, September 16, 2021 - 2:00pm

SÃO PAULO, Sept. 16, 2021 /PRNewswire/ -- Gerdau Graphene's research outpost at the Graphene Engineering Innovation Centre (GEIC) in the University of Manchester in the United Kingdom has just gained a new leadership. The renowned Scientist, Nurul Alam, PhD in Nanotechnology and Materials Science, now commands the company's Research Center as Gerdau Graphene's European CTO. With degrees from the British universities of Cambridge and Nottingham and a fellow of the Royal Society of Chemistry, the materials engineer is one of the world's leading plastic researchers.

Key Points: 
  • The renowned Scientist, Nurul Alam, PhD in Nanotechnology and Materials Science, now commands the company's Research Center as Gerdau Graphene's European CTO.
  • Researching graphene for four years, Gerdau, the largest Brazilian steel producer, has been operating since 2019 within the University of Manchester.
  • In 2021, it launched Gerdau Graphene, a company focused on the application, development, and marketing of graphene enhanced products, with its innumerous potential end products.
  • Gerdau Graphene is a company launched by Gerdau through Gerdau Next, its new business arm.

Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum

Wednesday, September 15, 2021 - 1:03pm

The Life Science Investor Forum is a live, interactive, online event where investors are invited to ask the company questions in real-time.

Key Points: 
  • The Life Science Investor Forum is a live, interactive, online event where investors are invited to ask the company questions in real-time.
  • It is recommended that investors pre-register for the forum and run the online system check to expedite participation and receive event updates.
  • More information about the Life Science Investor Forum is available at www.lifesciencesinvestorforum.com.
  • Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options.

Hong Kong Investor Relations Association Announces Winners of the 7th IR Awards 2021

Tuesday, September 14, 2021 - 1:01pm

Now in its seventh consecutive year, the Awards has been recognising and honouring investor relations ("IR") excellence and best practices among Hong Kong listed companies and IR professionals.

Key Points: 
  • Now in its seventh consecutive year, the Awards has been recognising and honouring investor relations ("IR") excellence and best practices among Hong Kong listed companies and IR professionals.
  • The 7th IR Awards 2021 enjoyed widespread support from listed companies and the investment sector.
  • The IR Pledge Program is designed to recognize Hong Kong listed companies with commitment to follow best practices in investor relations.
  • Strategic Public Relations Group is once again proud to be the Official Public Relations Partner and Diamond Sponsor of HKIRA IR Awards 2021.

Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors

Monday, September 13, 2021 - 10:00am

HMBD-002 accomplishes this without depleting VISTA expressing immune cells that play important roles in the immune response.

Key Points: 
  • HMBD-002 accomplishes this without depleting VISTA expressing immune cells that play important roles in the immune response.
  • Pre-clinical studies also show that HMBD-002 as a monotherapy, and in combination with pembrolizumab (an immune checkpoint inhibitor), significantly inhibited tumor growth, with no observed toxicity.
  • The Phase 1, multi-center, open-label trial will evaluate HMBD-002, as a monotherapy and in combination with pembrolizumab.
  • Hummingbird Bioscience is a clinical-stage biotechnology company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes.

Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters

Wednesday, September 8, 2021 - 12:00pm

MALVERN, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer, today announced final results from its Phase 1/2 pilot trial of its dismutase mimetic, GC4419, versus placebo, in patients with unresectable or borderline resectable locally advanced pancreatic cancer (LAPC), who are undergoing stereotactic body radiation therapy (SBRT). The results include a minimum of one year of follow up on all 42 patients enrolled in the trial.

Key Points: 
  • The results include a minimum of one year of follow up on all 42 patients enrolled in the trial.
  • For more information related to this trial, please see the Companys updated corporate presentation on the Investors page of Galeras website at investors.galeratx.com .
  • We are very pleased with the survival and tumor outcome benefits observed in the final analysis of this proof-of-concept trial, said Mel Sorensen, M.D., President and CEO of Galera.
  • The improvements across multiple efficacy parameters, together with the safety data, are encouraging and underpin the rationale for our 160-patient blinded, randomized GRECO-2 trial of GC4711 with SBRT in pancreatic cancer, where the primary endpoint is overall survival.

Today's HR Technologies Are More Likely To Be Geared Toward Employees than HR Professionals - New Study by the HR Research Institute

Friday, September 3, 2021 - 6:00pm

HR professionals have had to adapt quickly, using technology to better serve remote workers and support virtual teams.

Key Points: 
  • HR professionals have had to adapt quickly, using technology to better serve remote workers and support virtual teams.
  • The free research report, The State of Today's HR Tech Stack 2021 , is now available for download.
  • HR.com's Research Institute conducted the study of HR professionals to examine and track the state of HR technology stacks and to understand the required focus for managing human resource systems in the future.
  • HR.com's HR Research Institute helps HR departments keep their finger on the pulse of HR!

CRB joins Umoja Biopharma to Celebrate the Beginning of Construction at Development and Manufacturing Site

Tuesday, August 31, 2021 - 2:00pm

LOUISVILLE, Colo., Aug. 31, 2021 /PRNewswire/ --On Monday, August 30, Umoja Biopharma and CRB officially kicked off the construction of a 146,000 square foot development and clinical manufacturing facility.

Key Points: 
  • LOUISVILLE, Colo., Aug. 31, 2021 /PRNewswire/ --On Monday, August 30, Umoja Biopharma and CRB officially kicked off the construction of a 146,000 square foot development and clinical manufacturing facility.
  • Andy Scharenberg, M.D., Umoja Biopharma Co-founder & CEO, and members of the CRB and Umoja project team opened the event with a project tour and overview.
  • Attendees included government and economic development officials, business partners and members of the CRB project team and Umoja Biopharma leadership.
  • CRB will transform the existing building into 146,000 square feet of highly flexible and scalable manufacturing, laboratory, office, and warehouse space.